Progranulin is a potential prognostic biomarker in advanced epithelial ovarian cancers

This publication has 41 references indexed in Scilit:

• Current state of biomarker development for clinical application in epithelial ovarian cancer
  Gynecologic Oncology, 2010
• Secretory Leukocyte Protease Inhibitor Antagonizes Paclitaxel in Ovarian Cancer Cells
  Clinical Cancer Research, 2010
• Assessing Lead Time of Selected Ovarian Cancer Biomarkers: A Nested Case–Control Study
  JNCI Journal of the National Cancer Institute, 2010
• Ovarian Cancer
  International Journal of Gynecologic Cancer, 2009
• Overexpression of protease inhibitor‐dead secretory leukocyte protease inhibitor causes more aggressive ovarian cancer in vitro and in vivo
  Cancer Science, 2009
• Risk of recurrence during follow-up for optimally treated advanced epithelial ovarian cancer (EOC) with a low-level increase of serum CA-125 levels
  Annals of Oncology, 2008
• Nadir CA-125 concentration in the normal range as an independent prognostic factor for optimally treated advanced epithelial ovarian cancer
  Annals of Oncology, 2007
• Change in CA 125 levels after the first cycle of induction chemotherapy is an independent predictor of epithelial ovarian tumour outcome
  Annals of Oncology, 2007
• Carcinoma of the Ovary
  International Journal of Gynecology & Obstetrics, 2006
• A Radioimmunoassay Using a Monoclonal Antibody to Monitor the Course of Epithelial Ovarian Cancer
  New England Journal of Medicine, 1983